The US Food and Drug Administration (FDA) has slapped a clinical hold on US biotech Arcellx’ (Nasdaq: ACLX) CART-ddBCMA investigational new drug (IND) for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).
Arcellx, which is reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, saw its shares fall 8.5% to $32.74 by mid-morning today, the first Nasdaq trading since its announcement.
The clinical hold was received on June 16, following a recent patient death, the company explained. Arcellx believes limitations on bridging therapy are a contributing factor and is working with FDA to amend the protocol to expand options for patients that are consistent with current clinical practice. The FDA has provided clearance to Arcellx to continue to dose patients who have undergone lymphodepletion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze